Weekly Digest – July 2026 Weekly Digest – July 2026 29 June 2026: Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors The European Union has approved Enhertu as the […]
Weekly Digest – July 2026 Weekly Digest – July 2026 26 June 2026: Datroway recommended for approval in the EU as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy AstraZeneca and Daiichi Sankyo’s Datroway has […]
Weekly Digest – July 2026 Weekly Digest – July 2026 02 July 2026: SYS6043 granted BTD in China for the treatment of platinum-resistant Ovarian cancer CSPC Pharmaceutical Group has received Breakthrough Therapy Designation from China’s NMPA for SYS6043, a B7-H3-targeted […]
Weekly Digest – July 2026 Weekly Digest – July 2026 02 July 2026: FDA alignment to advance ProstACT Global phase 3 trial Telix Pharmaceuticals has reached alignment with the U.S. FDA to advance the ProstACT Global phase 3 trial of […]
Weekly Digest – July 2026 Weekly Digest – July 2026 02 July 2026: Glenmark advances phase 3 trial of Trastuzumab rezetecan in platinum-resistant Ovarian cancer Glenmark has advanced the multi-country phase 3 clinical trial of SHR-A1811, a HER2-targeted antibody-drug conjugate, […]
Weekly Digest – July 2026 Weekly Digest – July 2026 30 June 2026: CSPC initiates phase 3 trial of SYS-6010 in combination with Enlonstobart in resected stage II–IIIB NSCLC CSPC Pharmaceutical Group has initiated the phase 3 SYS6010-015 trial in […]
